Genesis Drug Discovery & Development, the contract research organisation unit of Genesis Biotechnology Group, announced on Thursday that it has named Anthony Rohr as its new chief operating officer.
Rohr is to offer operational leadership, oversight, and coordination across all Genesis Drug Discovery & Development member companies in this role. He has served as business development manager for GBG, chief executive officer of PharmOptima, and senior director of operations at MPI Research, Inc. He has 20 years of experience in the pharmaceutical, biotechnology, and CRO industries.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer